Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by an educational grant from Incyte Corporation.

Burst CME™: Integrating New Therapeutic Options Into Treatment Paradigms for Relapsed/Refractory DLBCL

Release Date: May 14, 2021
Expiration Date:  May 14, 2022

Activity Overview

Non-Hodgkin lymphoma (NHL) comprises a diverse group of lymphoproliferative disorders that can occur at any age. Diffuse large B-cell lymphoma (DLBCL) is one of the most common forms of NHL, accounting for approximately 30% of cases. In about 40% of patients with DLBCL, relapse or refractory disease will occur after first-line treatment. The current standard of care after relapse is intensive salvage treatment, followed by autologous stem cell transplant; however, 60% or more of patients will be transplant ineligible. The clinician is then faced with a growing array of advanced treatment options for the management of relapsed/refractory (RR) DLBCL, including polatuzumab vedotin with bendamustine plus rituximab, selinexor, single-agent ibrutinib, and the combination of lenalidomide with or without rituximab. Moreover, CAR T-cell therapy is now also a therapeutic reality. Other agents reporting late-stage phase 3 data include the PI3K inhibitors, anti-CD19 monoclonal antibodies, immunomodulatory drugs, and checkpoint inhibitors.

This Community Practice Connections activity provides an in-depth review of the latest clinical data and encourages access to the latest therapies through enrollment of eligible patients in clinical trials in an area of unmet need that must be met through education. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with R/R DLBCL, placing recent clinical trial data into a clinical context.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Incyte Corporation.


Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational program is directed toward medical oncologists and hematologists who treat or are interested in the treatment of diffuse large B-cell lymphoma (DLBCL). Other allied health care professionals, including nurse practitioners, physician assistants, and nurses involved in the treatment and management of patients with DLBCL will also be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Determine the diagnostic and prognostic biomarkers for DLBCL, and their utility in guiding treatment decision-making and patient management
  • Integrate new treatment options into evolving treatment algorithms for patients with relapsed/refractory DLBCL, taking into consideration efficacy, safety, and patient-specific factors, to optimize patient outcomes
  • Incorporate proactive strategies to mitigate, monitor, and manage adverse events associated with novel therapies used in the treatment of patients with DLBCL
  • Consider ongoing clinical trials of investigational agents for DLBCL, and how results from these trials may affect current treatment paradigms

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible entities.


Kami Maddocks, MD
Kami Maddocks, MD
Associate Professor of Clinical Internal Medicine
Lymphoma Program Director
Director OSUCCC Lymphoma Research
Department of Internal Medicine
Division of Hematology
The Ohio State University, The James Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio
Disclosures:Grant/Research Support: ADC, BeiGene, Celgene, Karyopharm, Kite/Gilead, MorphoSys, Pharmacyclics. Speaker's Bureau: Advisor/Speaker.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By